摘要
Objective:To observe the clinical efficacy and safety of butylphthalide joint human albumin in the treatment of the progress of type in acute cerebral infarction(PTCI).Methods:120 patients with PTCI in Department of Neurology of Shuyang People's Hospital were used to observe the efficacy.These patients were all treated by routine medicine including anti-platelet,statins,edaravone,ginkgo leaf extract and dipyridamole after admission.According to whether used butylphthalide and(or)human albumin in the treatment of PTCI,the patients were divided into A group 30 cases,B group 45 cases,and C group 45 cases.Patients of group C were given conventional treatment.Group B were given conventional treatment and human albumin injection(5 g,ivgtt,qd,3 days in a course);Group A were treated with butylphthalide(first,with butylphthalide and sodium chloride injection 100 ml,ivgtt,for 7 d,then with butylphthalide soft capsules 0.2 g,tid,for 21 d),human albumin(5 g,ivgtt,qd,for 3 d)and routine medicine.The change of NIHSS score,Barthel Index,and mRS of three groups respectively during progress,1 week,2 weeks and 90 days after progress were observed and analyzed.Results:NIHSS score,Barthel Index,and mRS of group A,group B and group C all showed no statistically significant(all p>0.05)on 1 week after treatment;NIHSS score and mRS of group A were both lower than group B and group C on 2 weeks and 90 days after treatment,and both of them showed statistically significant(p<0.05);Barthel Index of group A was higher than group B and group C on 90 days after treatment,it showed statistically significant(p<0.05);The total effective rate of group A(96.7%)>group B(88.9%)>group C(77.8%),showed statistically significant(p<0.05).Conclusions:Butylphthalide joint human albumin treatment of PTCI has good therapeutic effect and safety,it is useful to clinical promotion and further research.
